High Levels and Safety of Oseltamivir Carboxylate Plasma Concentrations after Nasogastric Administration in Critically Ill Children in a Pediatric Intensive Care Unit-Reference-Cited by-同舟云学术

High Levels and Safety of Oseltamivir Carboxylate Plasma Concentrations after Nasogastric Administration in Critically Ill Children in a Pediatric Intensive Care Unit

Published:2010-10-11 Issue:1 Volume:55 Page:433-435
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob. Agents Chemother.

Author:

Giraud Carole,Manceau Sandra,Oualha Mehdi,Chappuy Hélène,Mogenet Agnès,Duchêne Patrick,Ducrocq Sarah,Hubert Philippe,Treluyer Jean M.

Abstract

ABSTRACTDuring the 2009 H1N1 influenza pandemics, the concentrations of oseltamivir (O) and its active metabolite (oseltamivir carboxylate [OC]) were determined in 11 children (1 month to 16 years of age) admitted to intensive care units for presumed severe H1N1 infection. They received oseltamivir phosphate (OP) nasogastrically at doses between 1.5 and 6.8 mg/kg of body weight. High OC concentrations were found, with a mean level of 678 ± 535 μg/liter. The mean OP concentration was 27 ± 52 μg/liter. No marked side effect was reported.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Reference21 articles.

1. Abe, M., J. Smith, A. Urae, J. Barrett, H. Kinoshita, and C. R. Rayner. 2006. Pharmacokinetics of oseltamivir in young and very elderly subjects. Ann. Pharmacother. 40:1724-1730.

2. Acosta, E. P., P. Jester, P. Gal, J. Wimmer, J. Wade, R. J. Whitley, and D. W. Kimberlin. 2010. Oseltamivir dosing for influenza infection in premature neonates. J. Infect. Dis. 202:563-566.

3. Ariano, R. E., D. S. Sitar, S. A. Zelenitsky, R. Zarychanski, A. Pisipati, S. Ahern, S. Kanji, J. Rello, and A. Kumar. 2010. Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. CMAJ 182:357-363.

4. Bantia, S., C. D. Parker, S. L. Ananth, L. L. Horn, K. Andries, P. Chand, P. L. Kotian, A. Dehghani, Y. El-Kattan, T. Lin, T. L. Hutchison, J. A. Montgomery, D. L. Kellog, and Y. S. Babu. 2001. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob. Agents Chemother. 45:1162-1167.

5. Brewster, M., J. R. Smith, R. Dutkowski, and R. Robson. 2006. Active metabolite from Tamiflu solution is bioequivalent to that from capsule delivery in healthy volunteers: a cross-over, randomised, open-label study. Vaccine 24:6660-6663.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of etiotropic therapy in the treatment and prevention of influenza complications amidst the COVID-19 pandemic;Meditsinskiy sovet = Medical Council;2021-12-01

2. Route of Oseltamivir Administration Affects Metabolite Concentrations in Critically Ill Children;The Pediatric Infectious Disease Journal;2019-12

3. Influenza virus-related critical illness: prevention, diagnosis, treatment;Critical Care;2019-06-12

4. Influenza and the use of oseltamivir in children;Türk Pediatri Arşivi;2016-05-04

5. A prospective observational study of oseltamivir safety and tolerability in infants and young children ≤24 months;Pharmacoepidemiology and Drug Safety;2014-10-21